Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06752759 · ClinicalTrials.gov registry record · Phase 3
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
A Phase 3 study of Peripheral Nervous System Agents and Ketamine, sponsored by Theresa Jacob, PhD, MPH.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06752759 is a Phase 3 study of Peripheral Nervous System Agents and Ketamine that is actively recruiting participants, run by Theresa Jacob, PhD, MPH. The registered enrollment target is 40 participants, below the 315-participant average among 3 other Peripheral Nervous System Agents trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06752759, a Phase 3 study of Peripheral Nervous System Agents and Ketamine, is actively recruiting participants, sponsored by Theresa Jacob, PhD, MPH.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double blind active placebo controlled clinical trial for individuals within an inpatient setting with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
Conditions Studied
Interventions
- DRUG nebulized ketamine
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06752759
The ClinicalTrials.gov registry entry for NCT06752759 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 315-participant average among 3 other Peripheral Nervous System Agents trials with a reported enrollment target (87% lower). The listed sponsor is Theresa Jacob, PhD, MPH, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Peripheral Nervous System Agents appearing as the primary indexed condition, and to 1 intervention - of which nebulized ketamine is the first listed.
NCT06752759 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06752759 about?
NCT06752759 is a clinical study titled "Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting". This is a double blind active placebo controlled clinical trial for individuals within an inpatient setting with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
What is the current status of trial NCT06752759?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2024-10-16. Estimated completion is 2026-09-30.
What conditions does trial NCT06752759 study?
This clinical trial studies the following conditions: Peripheral Nervous System Agents, Ketamine, Neurotransmitter Agents, Physiologic Effects of Drugs, Moderate Depression.
What interventions are being tested in trial NCT06752759?
The interventions under investigation include: nebulized ketamine (DRUG).
Who is sponsoring clinical trial NCT06752759?
This trial is sponsored by Theresa Jacob, PhD, MPH, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06752759 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Nervous System Agents
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
RECRUITING · Phase 3
-
Natural History of Depression, Bipolar Disorder and Suicide Risk
RECRUITING
-
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.